Even clinicians who are not as familiar with these medications will ask me, 'I have a patient on Mounjaro who's not losing weight can we switch to Zepbound? without realizing its exactly the same drug. To complicate matters, pharmaceutical companies are quickly working on new drugs including triple agonists that target GLP-1, GIP and glucagon receptors as well as oral versions of each drug
Adipose tissue acts as both thermal insulation and an active endocrine organ that helps regulate body temperature
As of 2025, retatrutide has not received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for routine clinical use in the UK
If you drink, eat first, start with less than your usual amount, and stay hydrated
In a normally functioning body, GLP-1 gets released after eating
Through GLP-1 and GIP receptor agonism, retatrutide augments glucose-dependent insulin secretion and improves the function of the pancreatic beta cell, while GLP-1 signaling also suppresses inappropriate glucagon secretion in the fed state
.png)
